Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24035522 | 0.88 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL24035535 | 0.85 | POLB (0.34) | GAASMN1; SMN2ALDH1A1KDM4EEGLN1 | |
| SCHEMBL24031578 | 0.78 | GAA (0.34) | GAASMN1; SMN2ALDH1A1KDM4EFFAR1 | |
| SCHEMBL30161775 | 0.75 | ALDH1A1 (0.31) | ALDH1A1KDM4EFFAR1CPT2TDP1 | |
| SCHEMBL9463510 | 0.67 | HPGD (0.32) | ALDH1A1 | |
| SCHEMBL27344325 | 0.67 | CSNK2A1 (0.36) | — | |
| SCHEMBL24035650 | 0.67 | GAA (0.34) | GAASMN1; SMN2 | |
| SCHEMBL27324889 | 0.65 | MEN1 (0.36) | — | |
| SCHEMBL24031584 | 0.64 | GAA (0.34) | GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27408540 | 0.64 | GPR119 (0.38) | EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2021227904-A1 | POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | CDK9, CDK8, CDK19 | GAA 4269/4885SMN1; SMN2 4642/4885ALDH1A1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.